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The public health community is increasingly concerned about
the emergence of untreatable diseases due to infections caused
by resistant pathogenic bacteria. Increasing the dose can overcome
resistance to some extent, but a point is reached when the required
dose is no longer practical, safe or affordable. The disease is then
considered untreatable, unless an alternative effective antimicro-
bial with a different mechanism of action is available. This latter
option is becoming increasingly scarce as bacteria develop resis-
tance to multiple antimicrobial drugs, and the pipeline of new
drugs runs dry. As a result, veterinarians are limited in their op-
tions for the treatment of bacterial disease in their animal patients,
particularly food-producing animals, as the use of antimicrobials
becomes restricted in these species to ensure the continued efﬁ-
cacy of the drugs in human patients.
The conventional measure of a target pathogen’s sensitivity to
an antimicrobial drug is the minimum concentration that will inhi-
bit visible growth in vitro after overnight incubation (MIC). Stan-
dard procedures for determining MICs are well described and are
based on exposure of bacterial cultures to serial dilutions of anti-
microbial concentrations (Andrews, 2001). Strains of target bacte-
ria are then classiﬁed as susceptible, intermediate or resistant
based on the value of the MIC, with resistant strains having MICs
that are too high to be clinically treatable with the tested antimi-
crobial (Sirot et al., 2008). The values of the MIC that places a strain
in one of these three categories are based on recommendations by
national committees such as CLSI1 in the United States.
The complex relationship between antimicrobial drug concen-
trations and their inhibitory/killing effect on target bacteria is
greatly simpliﬁed when it is distilled to a single parameter, the
MIC. More complex, multi-parameter mathematical models have
therefore been developed by several authors to characterize thisrelationship (Czok and Keller, 2007). One of these models is based
on a Hill function that describes the antimicrobial–bacterial phar-
macodynamic relationship with four parameters (Regoes et al.,
2004). To estimate these parameters, the model is ﬁtted to
in vitro time-kill data, which are generated by exposing exponen-
tially growing bacteria to a range of drug concentrations and mon-
itoring the changes in density of viable cells over time. Analysis of
this model shows that, in addition to the MIC, the steepness of the
Hill function and minimum bacterial net growth rate at high anti-
microbial concentrations are important descriptors of the pharma-
codynamic relationship. Differences in these latter two parameters
can result in profound differences in the microbiological efﬁcacy of
antimicrobials with identical MICs.Optimizing antimicrobial dosage regimens
The disadvantage of describing the antimicrobial–bacterial
pharmacodynamic relationship with a single parameter is over-
come, at least to some extent, by classifying different antimicrobial
drugs as being either ‘time-dependent’ or ‘concentration-depen-
dent’. For ‘time-dependent’ antimicrobials, it is important that
drug concentrations are kept above target levels (typically the
MIC) for prolonged periods of time to ensure clinical efﬁcacy. For
‘concentration-dependent’ antimicrobials, high peak concentra-
tions (Cmax) and/or total exposure (as measured by the area under
the plasma time–concentration curve or AUC) are more predictive
of positive clinical outcomes (Martinez et al., 2006). When data are
available to describe the full relationship, drugs classiﬁed as ‘con-
centration-dependent’ typically have steep Hill functions and low
minimum bacterial net growth at high drug concentrations,
whereas drugs classiﬁed as ‘time-dependent’ have less steep Hill
functions and higher minimum bacterial net growth (Regoes
et al., 2004).
Within this paradigm of classifying antimicrobials as either
‘time-’ or ‘concentration-dependent’, rational dosage regimens
are designed by targeting speciﬁc values for two different indices.
For ‘time-dependent’ drugs, the index is the time between dose
administrations that the drug concentration (either in plasma or
at the site of action) is above the MIC (T > MIC). Target values for
this index are approximately 50–80% (Toutain et al., 2002). For
‘concentration-dependent’ drugs there are two indices, the AUC/
Table 1
Parameter values for a pharmacodynamic model based on the Hill function for selected antimicrobial drugs and bacteria reported in the literature (adapted from Czok and Keller,
2007).
Drug Micro-organism MIC (lg/mL) Kgrowth 0 1/h Kkill max 1/h EC50 (lg/mL) H Reference
Ceﬁxime Streptococcus pneumoniae ATCC 6303 0.3 1.4 3.0 0.3 3a Liu et al. (2005)
Ceﬁxime Streptococcus pneumoniae ATCC 49613 1.0 0.9 1.7 0.7 3a Liu et al. (2005)
Ciproﬂoxacin Escherichia coli (clinical isolate) 0.03 2.6 8.5 0.04 2.5 Meagher et al. (2004)
Ciproﬂoxacin Escherichia coli (clinical isolate) 0.5 1.0 7.6 0.1/1.8b 2.3 Meagher et al. (2004)
Ciproﬂoxacin Escherichia coli (clinical isolate) 2.0 0.3 8.6 1.9 1.8 Meagher et al. (2004)
Ciproﬂoxacin Escherichia coli O18:K1:H7 0.03 0.9 7.4 0.1 1.1 Regoes et al. (2004)
Gentamicin Pseudomonas aeruginosa ATCC 27853 2 0.5 4.7 0.7/31.3c 3.7 Tam et al. (2006)
Gentamicin Staphylococcus aureus (ﬁve strains)d 1 0.16 10.2 2.6 1.3 Tam et al. (2006)
a Fixed and not estimated.
b If two estimates are given, the ﬁrst refers to the susceptible and the second to the resistant population.
c Value for the resistant bacteria calculated using the maximum adaptation factor.
d Median values derived for different bacterial strains (ATCC 29213 and four clinical isolates).
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10–12, respectively (Toutain et al., 2002). Consequently, ‘time-
dependent’ antimicrobials are administered more frequently but
at lower doses, whereas ‘concentration-dependent’ antimicrobials
are administered less frequently but at higher doses. If the target
pathogen becomes less susceptible to the antimicrobial, (i.e., the
MIC increases), doses are increased so that target values for the
indices can once again be achieved. However, other aspects of
the dosage regimen (e.g., dosing interval) are rarely changed as
the classiﬁcation of the antimicrobial drug is assumed to remain
the same.
This approach to dosage regimen design is based on the assump-
tion that, for a given antimicrobial drug, the only difference in its
pharmacodynamic relationship with different bacterial strains is
the MIC. However, this assumption is not supported by experimen-
tal data. Instead, there is evidence in the literature (albeit sparse)
that both the steepness of the Hill function and the minimum bac-
terial growth rate at high antimicrobial concentrations may be dif-
ferent between different strains of bacteria of the same species as
well as between bacteria of different species (Table 1). This is not
surprising if resistance induces new biochemical mechanisms that
modulate the drug–effect interaction. In particular, for drugs con-
sidered to be ‘concentration-dependent’ (e.g., ﬂuoroquinolones
and aminoglycosides), the steepness of the Hill function appears
to becomes less steep with increasing MICs, suggesting that their
action may become more ‘time-dependent’, requiring an adjust-
ment of the dosing interval as well as the dose. In fact, adjusting
the dosing interval may result in a positive clinical outcome with-
out large increases in dose as the drug concentrations no longerFig. 1. Pharmacodynamic relationship between ciproﬂoxacin concentrations and its killin
in Czok and Keller, 2007).need to reach such high concentrations relative to the MIC, but
merely needs to be kept above the MIC. This issue deserves much
greater attention.
For example, using parameter estimates summarized by Czok
and Keller (2007) as a starting point, the pharmacodynamic rela-
tionship between ciproﬂoxacin and two different clinical isolates
of E. coli (one with an MIC of 0.03 and another with an MIC of
2 lg/mL) can be simulated (Fig. 1). Notice how not only the po-
tency (EC50), but also the maximal effect (Kkill max) and slope of
the relationship (H) change. In addition, the growth rate of the
resistant bacteria in the absence of antimicrobials is slower for
some of the isolates (Kgrowth 0), possibly due to the cost of carrying
and expressing resistance genes. A simulation that dynamically
links this full pharmacodynamic model based on the Hill equation
with a pharmacokinetic model of changing drug concentrations in
the plasma over time can be used to illustrate the consequence of
ignoring changes to multiple parameters in the pharmacodynamic
model.
Let us assume there are two different sub-populations in an
infection-causing inoculum (one highly susceptible with
MIC = 0.03 lg/mL, and one more resistant with an MIC = 2.0 lg/
mL) that differ not only in EC50 but also in the slope of their rela-
tionship to drug concentrations (H). Simulation of the outcome of
three different treatment regimens are illustrated in Figs. 2a–c.
Fig. 2a shows the outcome of treatment targeted at the suscepti-
ble isolate only. As expected, the susceptible population is suc-
cessfully controlled, whereas the more resistant population
continues to grow exponentially. Fig. 2b shows the outcome of
adjusting the dose to target the more resistant population by sim-g effect on two clinical isolates of Escherichia coli (based on parameters summarized
Fig. 2. Outcome of ciproﬂoxacin treatment targeted at the susceptible isolate of E. coli only (a), targeted at the resistant isolate of E. coli by increasing the dose only (b), and
targeted at the resistant isolate of E. coli by dividing the increased dose to be administered more often, thereby preventing concentrations from dropping to low trough values
(c).
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The more resistant population is now controlled, but not as well
as the susceptible population. Finally, Fig. 2c shows the outcome
of dividing the higher dose into smaller doses administered more
often. The total dose is the same as for the simulation for Fig. 2b,but the outcome is improved as resistant populations decline at a
rate more similar to susceptible populations. These simulations
show how consideration of the complete pharmacodynamic rela-
tionship can improve treatment outcomes within the constraints
of clinically feasible dosage regimens.
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The MIC remains the standard measure of antimicrobial drug
efﬁcacy and is relatively easy to determine experimentally. It has
disadvantages, however, because it is determined from a single sta-
tic measurement at one point in time during the growth of a bac-
terial inoculum, and it fails to describe fully the pharmacodynamic
relationship between the drug and microorganisms. When this
univariate parameter is then used to calculate indices that are pre-
dictive of clinical outcome, the measure is simpliﬁed even further,
because the dynamic nature of drug exposure and response rela-
tionship is ignored. Ideally, mathematical models that encompass
the dynamic nature of drug exposure and effect should be used
to predict clinical outcomes and derive clinical treatment strate-
gies (Czok and Keller, 2007). Currently, the data to drive these
models (time-kill curves for various antimicrobial drugs and target
strains of bacteria) are relatively sparse in the scientiﬁc literature,
partially because these studies are relatively more difﬁcult to per-
form. However, such research may become imperative with the
rise of untreatable bacterial infections in both man and animals,
and the scarcity of new treatment options on the horizon. It is cru-
cial that properly designed antimicrobial drug regimens are em-
ployed when resistant infections are being treated. This may
require using parameters that are more descriptive of the new sus-
ceptibility pattern and assessing whether the present binary classi-
ﬁcation of time or concentration dependent extends to bacteria
exhibiting resistance.References
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